Nevertheless, management has maintained its profit before tax guidance for the 2026 financial year, expecting significant ...

The UK-based footwear company said group revenue fell 3.1 percent on a reported basis to 251 million pounds in the third quarter.

Dr Martens expects sales to remain ‘broadly flat’ after strategic decision - Fashion brand has scaled back its discounts and ...

UK bootmaker Dr Martens said it expected full-year revenue to be broadly flat after a fall in third quarter sales, with ...

Stamping out discounting hjelps Dr Martens profits, Sage's recurring revenues tick higher, opportunities keep growing for ...

Dr Martens has unveiled a new strategic focus following a challenging year that nearly saw the brand slip into the red. The company will shift from a narrow focus on boots to a broader approach ...

Among the key news for UK stocks, Dr. Martens PLC (GB:DOCS) gained over 1% as of writing after the company reaffirmed its guidance for FY25. The company expects a double-digit percentage decline in ...

Dr. Martens shares briefly fell below their initial public offering price from a year ago after private-equity giant Permira sold a swathe of shares at a discount. Dr. Martens UK:DOCS shares slumped ...

On April 1, 1960, a small factory in Northamptonshire, England, pushed its first pair of boots off the line. Called the Dr. Martens 1460, this footwear would change the fashion and footwear industries ...

The firm saw shares dip in early trading as it said revenues were set to be broadly flat for the current year.

Mark Hartley analyses whether Dr Martens’ sharp share price rebound makes it one of the UK shares worth considering right now. But before getting too carried away, it’s worth remembering that the ...

Dr. Martens has said trading since the start of its financial year has been "in line with expectations" but the iconic shoe brand's UK business continues to suffer from a "challenging backdrop". The ...